IXCells Biotechnologies Unveils iPSCore™ Platform to Enhance Human Cell Model Generation
Thursday, June 12, 2025
iXCells Biotechnologies has launched its new iPSCore™ platform.
This modular system is designed to streamline the development of highly characterised human cell models derived from induced pluripotent stem cells (iPSCs).
The iPSCore™ platform integrates advanced tools, technical expertise and industry experience to develop iPSC-derived products using ethically sourced biospecimens, including cell fractions such as PBMCs or fibroblasts from both healthy individuals and patients. These cells can be reprogrammed, genetically modified, and differentiated into a wide range of cell types and 3D models, tailored to specific research or therapeutic needs.
The platform places strong emphasis on both descriptive and functional characterisation, enabling its use in a variety of downstream assays. Currently, iPSCore™ processes over 1,000 samples each year, achieving a success rate of more than 96%. Output is expected to significantly increase by 2026, particularly in patient-derived cell production.
iXCells developed this platform in response to the growing demand for relevant human cell models, which are often not readily available and require time-consuming design and engineering. The system supports the creation of both standard and customised cell products, with options for off-the-shelf or made-to-order availability.
The launch comes as the pharmaceutical and biotechnology sectors continue to shift towards alternatives to animal models. This trend is supported by the FDA Modernization Act 2.0, which permits the use of non-animal data for evaluating drug safety and efficacy. iPSC-derived models are increasingly viewed as more predictive and reliable, particularly for addressing unmet medical needs.
The introduction of iPSCore™ reflects iXCells’ commitment to harnessing the potential of iPSC technology. By combining cell reprogramming, editing, and differentiation with enhanced characterisation methods, the platform aims to replicate human biology more accurately in vitro.
This approach also lays the foundation for future innovations such as in vitro drug screening across diverse human genotypes and the integration of AI to identify disease-specific patterns—moving closer to the concept of "clinical trials on a plate".
Source: businesswire.com
